Clinical Observation on Modified Huqianwan in Treatment of Rheumatoid Arthritis Liver-kidney Yin Deficiency Syndrome

Jun-ping ZHAN; Hui-min GU; Qing-liang MENG; Rui-ting ZUO; Xu-zhao DU; Hui-lian WANG; Zi-peng ZHOU; Xi-yun MIAO; Wei FAN

doi:10.13422/j.cnki.syfjx.20182424

您当前的位置：

首页 >

文章列表页 >

Clinical Observation on Modified Huqianwan in Treatment of Rheumatoid Arthritis Liver-kidney Yin Deficiency Syndrome

Classic Prescriptions | 更新时间：2021-02-09

- Clinical Observation on Modified Huqianwan in Treatment of Rheumatoid Arthritis Liver-kidney Yin Deficiency Syndrome
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 25, Issue 1, Pages: 107-113(2019)
- 作者机构：
  
  河南省中医院，郑州　 450002
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20182424
  CLC： R22;R242;R2-031;R287
- Received：07 June 2018，
  
  Published Online：28 September 2018，
  
  Published：05 January 2019
- 稿件说明：
移动端阅览
Jun-ping ZHAN, Hui-min GU, Qing-liang MENG, et al. Clinical Observation on Modified Huqianwan in Treatment of Rheumatoid Arthritis Liver-kidney Yin Deficiency Syndrome[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(1): 107-113.
DOI：

Jun-ping ZHAN, Hui-min GU, Qing-liang MENG, et al. Clinical Observation on Modified Huqianwan in Treatment of Rheumatoid Arthritis Liver-kidney Yin Deficiency Syndrome[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(1): 107-113. DOI： 10.13422/j.cnki.syfjx.20182424.

摘要

目的：

观察虎潜丸加减治疗类风湿关节炎（RA）肝肾阴虚证的临床疗效及安全性。

方法：

将符合条件的184例肝肾阴虚型RA患者按照数字表法随机分为中药组（62例），西药组（57例）和中西药组（65例）。中药组给予虎潜丸加减治疗，西药组给予甲氨蝶呤片联合来氟米特片治疗，中西药组同时给予虎潜丸加减、甲氨蝶呤片及来氟米特片，疗程均为12周。比较各组治疗前后疼痛视觉模拟评分（VAS），28个关节的肿胀和压痛评分（DAS28），双手平均握力，晨僵时间和中医辨证肝肾阴虚证评分；测定各组治疗前后血沉（ESR），C反应蛋白（CRP），免疫球蛋白（Ig）G，肿瘤坏死因子-

（TNF-

）和类风湿因子（RF）等理化指标的变化；比较各组临床疗效及给药后的胃肠反应、肝损伤情况、白细胞减少、血清谷氨酸草酰乙酸氨基转移酶（GOT）及血小板（PLT）变化等不良反应情况，以考察各组药物的有效性和安全性。

结果：

治疗12周后，中药组、西药组、中西药组的临床疗效总有效率分别为79.0%，80.7%，92.3%，中西药组显著优于中药组及西药组（

0.01），中药组和西药组无明显差异；各治疗组均能有效改善RA患者的肝肾阴虚证（

0.05），其中中西药组优于中药组（

0.05），中药组优于西药组（

0.05）；不良反应的发生率中药组（1.61%，1/62）

中西药组（7.69%，5/65）

西药组（22.81%，13/57）。

结论：

虎潜丸加减治疗RA肝肾阴虚证的疗效与西药甲氨蝶呤片及来氟米特片联合用药的疗效无显著差异，且具有不良反应少的优点。虎潜丸加减结合西药甲氨蝶呤片及来氟米特片联合用药治疗RA肝肾阴虚证疗效优于西药甲氨蝶呤片及来氟米特。

Abstract

Objective:

To explore the clinical efficacy and safety of modified Huqianwan in treatment of rheumatoid arthritis (RA) liver-kidney Yin deficiency syndrome

and investigate its possible mechanism.

Method:

A total of 184 patients with RA liver-kidney Yin deficiency syndrome were randomly divided into Chinese medicine group (62 cases)

western medicine group (57 cases) and integrated Chinese and western medicine group (65 cases) according to the digital table method. The patients in Chinese medicine group were treated with Huqianwan; the patients in western medicine group were treated with methotrexate tablets and leflunomide tablets; and the patients in integrated Chinese and western medicine group received Huqianwan+ methotrexate tablets and leflunomide tablets

with a treatment course of 12 weeks in all groups. The pain visual analog scale (VAS)

swelling and tenderness scores of 28 joints (DAS28)

average hands grip strength

morning stiffness time and liver-kidney Yin deficiency syndrome differentiation of traditional Chinese medicine (TCM) syndrome score were compared between groups before and after treatment. The changes of erythrocyte sedimentation rate (ESR)

C reactive protein (CRP)

immunoglobulin (Ig)G

tumor necrosis factor-alpha (TNF-

) and rheumatoid factor (RF) were detected in all groups after treatment. Clinical efficacy

and incidence of adverse reactions such as gastrointestinal response

liver injury

leukopenia

serum glutamate oxaloacetic aminotransferase (GOT) and platelet (PLT) level changes were compared between the groups

so as to investigate the efficiency and safety of the different medicines.

Result:

After 12 weeks of treatment

the total clinical effective rate was 79.0%

80.7%

and 92.3% respectively in Chinese medicine group

western medicine group

and integrated Chinese and western medicine group; the integrated Chinese and western medicine group was significantly better than the Chinese medicine group and western medicine group (

0.01)

but there was no difference between the Chinese medicine group and western medicine group. Every treatment group can effectively improve liver and kidney Yin deficiency syndrome in RA patients (

0.05)

and the effect in integrated Chinese and western medicine group was superior to that in Chinese medicine group (

0.05); the effect in Chinese medicine group was superior to that in western medicine group (

0.05). The incidence of adverse reactions was Chinese medicine group (1.61%

1/62)

integrated Chinese and western medicine group (7.69%

5/65)

western medicine group (22.81%

13/57).

Conclusion:

The efficacy in treating RA liver and kidney Yin deficiency syndrome shows no significant difference between modified Huqianwan and methotrexate tablets+ leflunomide tablets. In the treatment of RA liver and kidney Yin deficiency syndrome

Huqianwan has fewer adverse reactions. Huqianwan combined with methotrexate tablets+ leflunomide tablets is superior to that in methotrexate tablets+ leflunomide tablets in treatment of RA liver-kidney Yin deficiency syndrome.

关键词

Keywords

references

Sandro M M , David A , Daniel A , et al . Myocellular characteristics in rheumatoid arthritis and osteoarthritis patients [J]. Arthritis Res Ther , 2018 , 20 ( 1 ): 51 - 52 .

都帅刚，郭中华，孔倩倩，等 . 散痹汤加减治疗类风湿关节炎肾虚寒湿证的临床研究 [J]．中国中药杂志， 2017 ， 42 ( 14 ): 2802 - 2807 .

Gulsen O , Diane L K , Ted R M , et al . Trends and determinants of osteoporosis treatment and screening in patients with rheumatoid arthritis compared to osteoarthritis [J]. Arthritis Care Res , 2018 , 70 ( 5 ): 713 - 723 .

ZHEN P , LI X S , ZHOU S H , et al . Total hip arthroplasty to treat acetabular protrusions secondary to rheumatoid arthritis [J]. J Orthop Surg Res , 2018 , 13 ( 1 ): 92 - 94 .

Karagülle M , Kardeş S , Dişçi R , et al . Spa therapy adjunct to pharmacotherapy is beneficial in rheumatoid arthritis: a crossover randomized controlled trial [J]. Int J Biometeorol , 2018 , 62 ( 2 ): 195 - 205 .

Versteeg G , Steunebrink L , Vonkeman H , et al . Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice [J]. Clin Rheumatol , 2018 , 37 ( 5 ): 1189 - 1197 .

Khatri A , Goss S , Jiang P , et al . Pharmacokinetics of ABT-122, a TNF- α - and IL-17A-targeted dual-variable domain immunoglobulin,in healthy subjects and patients with rheumatoid arthritis: results from three phase I trials [J]. Clin Pharmacokinet , 2018 , 57 ( 5 ): 613 - 623 .

张攀科，王芳，张国胜，等 . 小活络丹合桂枝芍药知母汤加减治疗风湿性关节炎寒湿痹阻证的临床观察 [J]．中国实验方剂学杂志， 2017 ， 23 ( 3 ): 181 - 186 .

McCarty D , Robinson A. Efficacy and safety of sarilumab in patients with active rheumatoid arthritis [J]. Ther Adv Musculoskelet Dis , 2018 , 10 ( 3 ): 61 - 67 .

Jeffrey R C , Mona T , Boulos H , et al . Defining and characterizing sustained remission in patients with rheumatoid arthritis [J]. Clin Rheumatol , 2018 , 37 ( 4 ): 885 - 893 .

王丽萍，王春燕，王晓元，等．复方玄驹胶囊联合甲氨蝶呤治疗难治性类风湿关节炎的临床研究 [J]. 中成药， 2018 ， 40 ( 2 ): 299 - 304 .

Kristen D M , Bowers E , Lauren J L , et al . Antibody responses to citrullinated and noncitrullinated antigens in the sputum of subjects with rheumatoid arthritis and subjects at risk for development of rheumatoid arthritis [J]. Arthritis Rheumatol , 2018 , 70 ( 4 ): 516 - 527 .

Curtis J R , Trivedi M , Haraoui B , et al . Defining and characterizing sustained remission in patients with rheumatoid arthritis [J]. Clin Rheumatol , 2018 , 37 ( 4 ): 885 - 893 .

中华人民共和国卫生部．中药新药临床研究指导原则 [M]．北京：人民卫生出版社， 1993 ： 115 - 119 .

ZHANG F Z , MA C L. Comparison of the effectiveness on intra-articular and subcutaneous TNF inhibitor in rheumatoid arthritis patients [J]. Clin Rheumatol , 2018 , 37 ( 1 ): 199 - 204 .

钱鑫，陈璇，魏刚，等．独活寄生汤联合美洛昔康治疗类风湿性关节炎临床观察 [J]．中国实验方剂学杂志， 2016 ， 22 ( 7 ): 173 - 176 .

Burggraaf B , Breukelen S D , Vries M , et al . Progression of subclinical atherosclerosis in subjects with rheumatoid arthritis and the metabolic syndrome [J]. Atherosclerosis , 2018 , 271 ( 1 ): 84 - 91 .

JIANG L , JIANG D D , HAN Y , et al . Association of HLA-DPB1 polymorphisms with rheumatoid arthritis: a systemic review and Meta-analysis [J]. Int J Surg , 2018 , 52 ( 1 ): 98 - 104 .

陈锋，闵重函，周瑛，等 . 蚁参蠲痹胶囊联合西药治疗肾气虚寒型类风湿关节炎35 例临床观察 [J]．中医杂志， 2016 ， 57 ( 12 ): 1045 - 1048 .

Cho S , Kim D , Won S , et al . Impact of anti-rheumatic treatment on cardiovascular risk in Asian patients with rheumatoid arthritis [J]. Semin Arthritis Rheum , 2018 , 47 ( 4 ): 501 - 506 .

XING R , SUN L , WU D , et al . Autoantibodies against interleukin-21 correlate with disease activity in patients with rheumatoid arthritis [J]. Clin Rheumatol , 2018 , 37 ( 1 ): 75 - 80 .

Sabry D , Kaddafy S , Abdelaziz A , et al . Association of SIRT-1 gene polymorphism and vitamin D level in egyptian patients with rheumatoid arthritis [J]. J Clin Med Res , 2018 , 10 ( 3 ): 189 - 195 .

Cecli Z. Clearing up potential misconceptions about the treatment of rheumatoid arthritis and the use of methotrexate in combination therapy [J]. Can Pharm J , 2018 , 151 ( 2 ): 94 - 97 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Editorial Explanation of Guidelines for Establishing Animal Models of Rheumatoid Arthritis with Cold-dampness Obstruction Syndrome and Dampness-heat Obstruction Syndrome

Guidelines for Establishing Animal Models of Rheumatoid Arthritis with Cold-dampness Obstruction Syndrome and Dampness-heat Obstruction Syndrome

Clinical Characteristics and Influencing Factors of Rheumatoid Arthritis in Patients with Cold Dampness Obstruction Syndrome

Pathogenesis and Traditional Chinese Medicine Treatment of Rheumatoid Arthritis Based on Theory of "Harmful Hyperactivity and Responding Inhibition"

Curative Effect of Tripterygium wilfordii Polyglycoside Tablets in Treatment of Rheumatoid Arthritis in Real World Based on Propensity Score Matching

Related Author

LIN Na

ZHANG Yanqiong

XIAO Changhong

XU Shijun

MAO Xia

Representation Preparation Group

TU Shenghao

SUN Jianning

Related Institution

Institute of Chinese Materia Medica，China Academy of Chinese Medical Sciences

Southern Medical University Hospital of Integrated Chinese and Western Medicine

Tongji Hospital， Tongji Medical College of Huazhong University of Science and Technology

School of Chinese Materia Medica， Beijing University of Chinese Medicine

School of Pharmacy，Chengdu University of Traditional Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰